Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921158 | 0.71 | CA2 (0.41) | CA2CA1SLC22A12PTGS1PTGS2 | |
| SCHEMBL29089521 | 0.70 | MEN1 (0.48) | CA2CA1 | |
| SCHEMBL5642510 | 0.68 | GAA (0.54) | CA2SLC22A12PTGS1PTGS2KDM1A | |
| SCHEMBL29948906 | 0.66 | CA2 (0.41) | CA2CA1SLC22A12PTGS1PTGS2 | |
| SCHEMBL18921160 | 0.66 | SLC22A12 (0.43) | CA2CA1SLC22A12PTGS1PTGS2 | |
| SCHEMBL2489790 | 0.65 | PTGS1 (0.45) | CA2CA1SLC22A12PTGS1PTGS2 | |
| SCHEMBL32682886 | 0.65 | JUN (0.40) | SLC22A12PTGS2 | |
| SCHEMBL23606964 | 0.65 | DYRK1A (0.39) | CA2CA1 | |
| SCHEMBL18921132 | 0.65 | CA2 (0.41) | CA2CA1SLC22A12PTGS1PTGS2 | |
| SCHEMBL21885794 | 0.65 | S1PR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363656-A1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-3383868-B1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363656-A1 | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | LTB4R2, LTB4R, LTC4S | CA2 3594/4885CA1 4853/4885SLC22A12 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.